AUS
NZ
UK
CA
USA
IND
Highlights
- Indivior PLC (LON:INDV) has announced the cancellation of its secondary listing on the London Stock Exchange.
- The company will maintain its primary listing on the Nasdaq Stock Market in the United States.
- The decision follows an evaluation of trading volumes, shareholder distribution, and administrative factors.
FTSE 100 Pharmaceutical Stock to Delist from London Exchange
Indivior PLC (LON:INDV), operating in the pharmaceutical sector, has confirmed its plan to cancel the secondary listing of its ordinary shares on the London Stock Exchange (LSE). The company will retain its primary listing on the Nasdaq Stock Market. The development follows an internal review conducted by Indivior’s board, assessing its listing structure in light of evolving shareholder demographics and trading activity. Indivior’s transition underscores a broader trend among globally-focused pharmaceutical firms reevaluating exchange listings in alignment with strategic commercial geographies. Comparable companies within related indexes, including the FTSE 100, continue to maintain exposure across multiple trading venues.
Details of the London Delisting
Indivior formally initiated the process to cancel the listing of its ordinary shares from both the Official List maintained by the UK Financial Conduct Authority (FCA) and the LSE’s main market for listed securities. This step is being taken in connection with its existing transition to the Nasdaq as its principal listing venue. The company has issued notice to the FCA and LSE to initiate the delisting process in line with regulatory procedures.
The decision terminates Indivior’s status as a dually listed entity. The move does not affect its ordinary shares' trading on Nasdaq, where the company has operated under its primary listing. The secondary listing on the LSE had been retained for structural and legacy reasons, even after the U.S. listing gained prominence.
Evaluation of Trading Volume and Shareholder Base
The company’s board reviewed the trading volumes of its ordinary shares on both the LSE and Nasdaq. The data indicated that trading activity on Nasdaq significantly exceeds that on the LSE. As of late May, approximately three-quarters of Indivior’s share trading volume occurred on the Nasdaq exchange.
Additionally, the board evaluated the geographical distribution of shareholders. Over seventy percent of Indivior’s ordinary shares by value are held by shareholders based in the United States. This concentration of ownership in the U.S. aligns with the company’s current commercial operations and future priorities. These factors contributed significantly to the decision to withdraw from the London market.
Cost and Administrative Considerations
In addition to evaluating liquidity and shareholder demographics, Indivior reviewed the ongoing costs associated with maintaining a secondary listing. The board determined that the administrative burden and financial costs linked to the LSE listing were no longer justified. Simplifying the listing structure is expected to reduce operational complexity.
The board also took into account the regulatory and procedural distinctions between U.S. and UK listing regimes. Aligning with a single jurisdiction for listing and disclosure requirements allows the company to streamline communications, especially around material news announcements.
Alignment with Strategic and Geographic Revenue Base
Indivior generates the majority of its revenue from the U.S. market, notably through its SUBLOCADE product line. The company stated that delisting from London enables it to better align its public disclosures and investor communications with its U.S.-centric revenue base.
The move is presented as a structural alignment with where the company operates and derives financial performance. This step is also positioned as a reflection of broader sector trends, with healthcare firms adapting their capital market structures to match their operational footprints.
Future Listing Structure and Market Presence
With the delisting process underway, Indivior will operate solely under its Nasdaq listing. The company emphasized that this streamlined structure is consistent with its strategic orientation toward the U.S. pharmaceutical market. The move also standardizes trading hours and aligns with the schedules of its peer companies listed exclusively in the U.S.
The change does not impact the company’s operations, product distribution, or corporate governance structure. It strictly addresses capital markets access and is not indicative of operational changes within the UK or Europe.
